Related Experiment Video
Updated: Sep 15, 2025
07:46
CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.
Published on: December 11, 2020
6.0K
CRISPR RiPCA for Investigating eIF4E-m7GpppX Capped mRNA Interactions
Gabriela Vega-Hernández1, Jesse Duque2, Brandon J C Klein3
1Program in Chemical Biology, University of Michigan, Ann Arbor, Michigan 48109, United States.
Biorxiv : the Preprint Server for Biology
|July 16, 2025
Summary
Researchers developed CRISPR RiPCA, a new platform for studying RNA-protein interactions in live cells. This tool measures the activity of cancer drug inhibitors targeting eukaryotic translation initiation factor 4E (eIF4E) RNA-binding proteins.
Area of Science:
- Molecular Biology
- Biochemistry
- Genetics
Background:
- Post-transcriptional modifications of mRNA are regulated by reader RNA-binding proteins (RBPs).
- Dysregulation of RBPs is linked to diseases like cancer, neurodegeneration, and viral infections.
- Targeting RBPs offers a therapeutic strategy for restoring normal RNA processing and function.
Purpose of the Study:
- To develop a novel platform for live-cell RNA-protein interaction (RPI) analysis.
- To couple CRISPR technology with the RNA interaction with Protein-mediated Complementation Assay (RiPCA).
- To create a tool for assessing the activity of potential therapeutic agents.
Main Methods:
- Established a live-cell RPI assay platform named CRISPR RiPCA.
- Utilized CRISPR technology integrated with the RiPCA assay.
- Modeled the system using the interaction between eukaryotic translation initiation factor 4E (eIF4E) and an m7G-capped RNA substrate.
Main Results:
- Demonstrated the potential of CRISPR RiPCA for measuring on-target activity.
- Successfully applied the eIF4E CRISPR RiPCA to study a specific RBP interaction.
- Showcased the technology's relevance for cancer drug discovery.
Conclusions:
- CRISPR RiPCA is a powerful new platform for studying RPIs in live cells.
- This technology enables the assessment of therapeutic interventions targeting RBPs.
- The developed platform holds significant promise for cancer drug discovery and other disease areas.
Related Concept Videos
02:53CRISPR and crRNAs
17.4K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.4K
01:28CRISPR/Cas9 Genome Editing
272
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
272
01:59CRISPR
53.0K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
53.0K